Taking a Step Further in Identifying Ideal Blood Pressure Range Among Hemodialysis Patients: A Systematic Review and a Meta-Analysis

Abstract

Background: Hypertension is one of the primary predictor of mortality among end-stage renal disease (ESRD) patients on dialysis. However, there is no consensus on an ideal blood pressure range for this population. Aims and Objective: To identify an ideal systolic blood pressure range based on optimal survival among ESRD patients on dialysis. Method: A systematic search for clinical trials assessing the impact of different systolic blood pressure range on mortality among ESRD patients on hemodialysis was conducted through PubMed, EBSCOhost, Science Direct, Google Scholar, and Scopus. All randomized control trials (RCTs) involving ESRD patients on hemodialysis with primary or secondary outcome of assessing the impact different systolic blood pressure range (< 140 and >140 mm Hg) on all-cause mortality were included. The quality of reporting of the included studies was evaluated using the Jadad scale. Two researchers independently conducted eligibility assessment. Discrepancies were resolved by discussion and consultation with a third researcher when needed. Pooled relative risks (RRs) with 95% confidence intervals (CIs) were calculated. Results: A total of 1,787 research articles were identified during the initial search, after which six RCTs met our inclusion criteria. According to the Jadad scale, all six RCTs scored 3 points each for quality of reporting. Four RCTs employed pharmacological intervention while two RCTs assessed non-pharmacological intervention. Of the six RCTs, two studies were able to achieve a systolic blood pressure of <140 mm Hg at the end of trial with a RR for reduction in mortality of 0.56 (95% CI, 0.3-1.07; P = 0.08). Four RCTs were able to achieve a systolic blood pressure of >140 mm Hg at the end of trial, with the RR for reduction of mortality of 0.72 (95% CI, 0.54-0.96; P = 0.003). Overall, pooled estimates of the six RCTs suggested the reduction in systolic blood pressure statistically reduce all cause of mortality (RR, 0.69%; 95% CI, 0.53-0.90; P = 0.006) among ESRD patients on hemodialysis. Conclusion: Though not statically significant, the current study identifies <140 mm Hg as a promising blood pressure range for optimum survival among ESRD patients on

Primary kidney disease modifies the effect of comorbidities on kidney replacement therapy patients’ survival

“…Underweight has previously been established to be associated with an increased risk of death, but the association between obesity and mortality among GN patients shown here, has not been published earlier [17][18][19][20]. Although treatment of hypertension reduces mortality among patients on hemodialysis [21], hypertension has been demonstrated to have an inverse association with mortality in epidemiological studies [6,22], which is in line with our results. This may be due to an increased risk of death associated with intradialytic hypotension [23].…”

A systematic review of the efficacy of donepezil hydrochloride combined with nimodipine on treating vascular dementia

“…Clinical trials within the studies included were evaluated by Cochrane risk of bias tool [7] : whether it is randomized; whether allocation method was concealed; whether both the participants and investigators were blinded; whether the results were drawn under double blinding; whether the data throughout the process to conclusion was complete; selective reporting of research results; other source of bias. All items evaluated as correct would be considered as low risk of bias.…”

Recent advances of gut microbiota in chronic kidney disease patients

“…Renal replacement therapies such as hemodialysis, peritoneal dialysis and renal transplantation are the mainstay therapies for patient with ESRD [101][102][103][104][105][106][107][108][109][110]. The dysbiosis of gut microbiota was involved in these renal replacement therapies [111][112][113][114].…”